By Fineline Cube 
US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong Limited is set to acquire 51% stakes in Hong Kong-headquartered InfiniClone Limited for USD 19.9 million. This strategic move underscores Shineco’s commitment to expanding its presence in the regenerative medicine sector.
InfiniClone’s Technology and Expertise
InfiniClone, a biotech company specializing in regenerative medicine, focuses on induced pluripotent stem cell (iPSC) technology and its applications. The company holds 29 global patents, including five invention patents, and has developed technologies that can increase cell expansion throughput by three to ten times compared to existing methods. These innovations highlight InfiniClone’s significant contributions to advancing regenerative medicine and cosmeceutical product development.-Fineline Info & Tech